Maxim Group Reiterates Buy Rating for Viking Therapeutics, Inc. (VKTX)
Viking Therapeutics, Inc. (NASDAQ:VKTX)‘s stock had its “buy” rating reaffirmed by Maxim Group in a note issued to investors on Wednesday. They presently have a $5.00 target price on the biotechnology company’s stock. Maxim Group’s target price indicates a potential upside of 164.55% from the company’s current price.
A number of other research firms have also recently weighed in on VKTX. HC Wainwright restated a “buy” rating and issued a $7.00 price target (up from $5.00) on shares of Viking Therapeutics in a report on Monday, July 17th. ValuEngine upgraded shares of Viking Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, September 7th.
Shares of Viking Therapeutics (VKTX) remained flat at $1.89 on Wednesday. 333,344 shares of the stock were exchanged. Viking Therapeutics has a one year low of $0.90 and a one year high of $2.01. The firm’s market cap is $52.35 million. The stock’s 50 day moving average price is $1.45 and its 200-day moving average price is $1.45.
Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). Equities analysts expect that Viking Therapeutics will post ($0.82) earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the stock. Virtu KCG Holdings LLC purchased a new position in shares of Viking Therapeutics in the 2nd quarter valued at approximately $124,000. Renaissance Technologies LLC raised its position in shares of Viking Therapeutics by 62.9% in the 1st quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock valued at $388,000 after purchasing an additional 102,600 shares during the last quarter. Finally, Sabby Management LLC purchased a new position in shares of Viking Therapeutics in the 2nd quarter valued at approximately $525,000. 5.67% of the stock is owned by hedge funds and other institutional investors.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Stock Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related stocks with our FREE daily email newsletter.